• About us
• Contact

Advertisement

Organisation › Details

Boehringer Ingelheim (Group)

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. *

 

	Start	1885-01-01 established
	Industry	pharmaceutical
	Region	Ingelheim
	Country	Germany
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-77-0
		Address record changed: 2025-04-23
Basic data	Employees	I: 50,001 to 100,0 (2025-12-31)
	Currency	EUR
	Annual sales	27,751,000,000 (sales, net, consolidated (2025) 2025-12-31)
		* Document for »About Section«: Boehringer Ingelheim. (4/3/25). "Press Release: Boehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio with New NBE Therapeutics R&D Center in Basel". Basel.
		Record changed: 2026-05-02

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Brainomix Ltd.. (5/12/26). "Press Release: Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis". Oxford & Chicago, IL....
• [2] Agilent Technologies Inc.. (2/11/26). "Press Release: Agilent Presents Boehringer Ingelheim with Inaugural 2025 Instrument Trade-In Impact Award". Santa Clara, CA....
• [3] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim and Zeiss Join Forces to Early Detect Eye Diseases and Prevent Vision Loss". Ingelheim & Jena....
• [4] Evotec SE. (7/6/22). "Press Release: Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance". Germany & France....
• [5] Brainomix Ltd.. (2/1/22). "Press Release: Brainomix Announces New Partnership with Boehringer Ingelheim to Develop AI-powered Radiomic Software for Automated Assessment of Solid Tumor Cancer". Oxford....
• [6] Biognosys AG. (7/23/20). "Press Release: Boehringer Ingelheim and Biognosys Join Forces on Applying Quantitative Proteomics Tools in Drug Discovery". Biberach & Schlieren....
• [7] Genedata AG. (2/26/20). "Press Release: Leading Biopharma Experts Drive R&D Innovation and Process Efficiency at the Genedata Partner Symposium". Basel....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2026. Made in Germany.